keratoconus. Other disorders of sclera and cornea in diseases classified elsewhere
Conditions
Interventions
Intervention 1: Intervention group: Patients are given oral riboflavin (400 mg daily, 100 mg tablets twice a day, two tablets each time) for 6 months. Intervention 2: Control group: Control group: Pat
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 25 Years
Inclusion criteria
Inclusion criteria: 20-25 years old patients with non-progressive keratoconus that doesnt have indication for CXL.
Exclusion criteria
Exclusion criteria: History of surgery in the study eye (transplant, CXL) K-MAX greater than 60 diopters (measured with a pentacam device (Oculus Optikgerate GmbH, Wetzlar, Germany)) Presence of active liver or kidney disease Presence of stress lines in the examination
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Kmax variable as an increase in topographic imaging. Timepoint: before, 3 months, and 6 months after the start of the intervention,. Method of measurement: Corneal topography devices, Pentacam, autorefractometer. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammadreza Ashtar
Mashhad University of Medical Sciences
Outcome results
None listed